Aptose Biosciences Inc (APTO)

[dcaf7]

Here is my takeaway from ASH presentation that I was trying to post on YMB with no success.
New Tuspetinib responses:
80 mg, patient S1403, PR after 3 cycles of treatment. This patient was alive for 8 more cycles or approximately 8 months. Question is why didn’t we see it in previous presentations?
120 mg, patient S1115, PR after 1 cycle, then death. Not very encouraging.
160 mg, patient S2208, PR after 3 cycles, death soon after.
160 mg, patient S2103, CRp after 3 cycles, patient is alive, treatment is ongoing. This is a real deal.
40 mg, patient S2404, CRi after 1 cycle, treatment is ongoing. Since only 2 patients are evaluable for response in 40 mg cohort, ORR is technically 50%. Interesting, what this dose will bring in future?
Overall, acceptable but not exciting.